首頁 > 市場調查報告書 > 醫療設備

醫院 IT 癌症

市場調查報告書

商品編碼

1918194

腫瘤資訊系統市場－2026-2031年預測

Oncology Information Systems Market - Forecast from 2026 to 2031

出版日期: 2026年01月16日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計腫瘤資訊系統市場將從 2025 年的 31.84 億美元成長到 2031 年的 47.95 億美元，複合年成長率為 7.06%。

腫瘤資訊系統（OIS）市場由專門設計的軟體平台組成，旨在管理癌症治療中複雜、數據密集和多學科的工作流程。這些系統如同現代腫瘤診療的中樞神經系統，整合患者數據、治療計劃、日程安排和治療結果追蹤，從而支持高風險治療領域的臨床決策、運營效率和合規性。

核心系統功能和臨床整合

腫瘤資訊系統（OIS）並非單一應用程式，而是一套針對腫瘤學特定需求量身定做的整合模組。其核心功能通常包括患者預約、帶有腫瘤學專用模板的電子健康記錄（EMR）、化療輸入和管理（CPOE）、放射治療計劃和記錄管理、臨床試驗管理以及治療結果分析。其根本價值在於創建貫穿整個治療過程的統一患者記錄，涵蓋從診斷和分期到手術、放射治療、全身治療和康復的各個階段，並確保外科腫瘤醫生、內科腫瘤醫生、放射腫瘤醫生、護士、藥劑師和劑量師之間的協作。

主要市場成長促進因素

市場擴張的根本驅動力是全球癌症負擔的日益加重，這導致患者管理的數量和複雜性不斷增加。隨著病例數量的成長，擴充性且高效的系統至關重要，這些系統能夠最大限度地減少錯誤、規範治療路徑並管理治療週期中複雜的物流，從而推動了對強大的光學資訊系統（OIS）解決方案的需求。

癌症治療方法的快速發展是推動組織免疫學（OIS）應用和完善的強大動力。向個人化醫療、生物標記指導治療以及結合放射療法、免疫療法和標靶藥物的複雜聯合療法的轉變，產生了大量多樣化的數據。現代組織免疫學平台對於管理這種複雜性至關重要，它可以追蹤基因組檢測結果，計算精確的藥物劑量和放射治療方案，並確保安全使用具有獨特毒性特徵的新型藥物。

技術融合是關鍵的成長方向。互通性標準（例如 HL7、FHIR）、雲端運算和資料分析的進步正在改變 OIS 的功能。與診斷成像系統 (PACS)、實驗室系統和基因組資料庫的整合，能夠提供全面的患者觀點。將人工智慧 (AI) 和機器學習融入到諸如放射治療計劃中的自動勾畫、患者風險分層的預測分析以及臨床決策支援等操作中，正推動 OIS 從一種管理工具轉變為一種智慧的臨床支援工具。

癌症治療模式正經歷著從價值導向到結果導向的巨大轉變，這推動了對先進數據收集和分析的需求。結果導向資訊系統（OIS）對於匯總真實世界證據、追蹤品質指標以及滿足支付方和腫瘤登記機構的要求至關重要，這些報告能夠證明治療的品質和成本效益。

在近期醫療服務模式發展趨勢的推動下，遠端醫療和遠距監測功能的整合已成為關鍵特性。腫瘤資訊系統（OIS）平台目前支援虛擬會診、遠距病患報告結果（PRO）收集和遠端醫療協調，從而擴大了腫瘤學專業知識的覆蓋範圍，並促進了診室外的持續護理管理。

市場限制和實施挑戰

市場面臨系統整合和資源限制的重大障礙。部署和維護線上資訊系統 (OIS) 需要大量的資金投入、專門的 IT 支援和廣泛的使用者培訓。將 OIS 與醫院現有的企業電子健康記錄 (EHR)、藥房和計費系統整合通常既複雜又耗時，而且成本高昂，並可能導致工作流程中斷。

此外，醫療保健基礎設施的差異可能會限制其應用：資源匱乏或位於農村地區的醫療機構可能缺乏資金、可靠的高速網際網路或先進的 OIS 平台所需的專業 IT 人員，從而在獲取這些操作工具方面造成數位落差。

按地區情況分類的採納模式

北美是一個成熟的大型市場，其特點是腫瘤治療支出高、早期採用數位醫療技術，以及複雜的監管和報銷環境，這需要強大的數據管理能力。主要腫瘤資訊系統供應商、整合的癌症網路以及對醫療資訊技術的巨額投資鞏固了該地區的主導地位。

在其他已開發地區和某些高成長市場，這種做法也在不斷普及，其動力來自國家癌症控制計劃、對集中式癌症中心的投資，以及對改善護理協調和數據收集以進行研發和公共衛生監測的需求。

競爭格局與策略演變

競爭格局包括專業的腫瘤軟體公司和設有腫瘤部門的大型醫療IT公司。差異化優勢體現在臨床功能的深度（特別是先進的放射治療計劃和複雜的全身治療管理）、無縫的互通性、用戶體驗以及強大的分析和報告模組。

我們的策略性措施主要集中在開發雲端原生平台以減輕診所的IT負擔，利用人工智慧擴展臨床工具，以及建立可擴展的模組化系統，使其能夠從社區診所擴展到大規模學術醫療中心。與製藥公司和臨床研究機構合作，簡化臨床實驗的病患招募和資料管理流程，也是我們日益重要的策略重點。

未來市場趨勢

未來，OIS市場的發展方向是提高智慧化程度、互通性並以患者為中心。 OIS將演變為預測性臨床作業系統，利用匯總資料來提案個人化治療方案，並識別有併發症和再入院風險的患者。

增強型病患入口網站和行動整合將賦予病患更多自主權，使其成為自身醫療照護的積極參與者。此外，支持分散式臨床試驗和產生真實世界證據的組織資訊系統（OIS）的作用也將顯著擴展。供應商的成功取決於能否透過提高營運效率、增強病患安全以及提供高品質、互聯互通的醫療支持，展現出清晰的投資回報。隨著腫瘤學日益數據驅動和多模態，作為支持高效、有效且公平的癌症診療服務的關鍵數位基礎設施，OIS市場有望持續成長。

本報告的主要優勢：

深入分析：獲取主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

它是用來做什麼的？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區分類的收入和預測評估，包括國家/地區
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 英國
- 德國
- 法國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 日本
- 中國
- 印度
- 韓國
- 印尼
- 泰國
- 其他

第9章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
供應商競爭力矩陣

第10章：公司簡介

Varian
RaySearch Laboratories
Seimens Healthineers
Elekta
Chiuhomed
Mckesson
IQVIA
Cerner
Philips
GE Healthcare

簡介目錄

Product Code: KSI061616023

Oncology Information Systems Market is expected to grow at a 7.06% CAGR, increasing from USD 3.184 billion in 2025 to USD 4.795 billion in 2031.

The oncology information systems (OIS) market comprises specialized software platforms designed to manage the complex, data-intensive, and multidisciplinary workflow of cancer care. These systems function as the central nervous system of modern oncology practices, integrating patient data, treatment planning, scheduling, and outcomes tracking to support clinical decision-making, operational efficiency, and compliance in a high-stakes therapeutic area.

Core System Function and Clinical Integration

An OIS is not a singular application but an integrated suite of modules tailored to oncology's unique demands. Core functionalities typically include patient scheduling, electronic medical records (EMR) with oncology-specific templates, chemotherapy order entry and management (CPOE), radiation therapy planning and record-keeping, clinical trial management, and outcomes analysis. Its fundamental value lies in creating a unified patient record across the care continuum-from diagnosis and staging through surgery, radiation, systemic therapy, and survivorship-ensuring coordination among surgical, medical, and radiation oncologists, nurses, pharmacists, and dosimetrists.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global burden of cancer, which increases the volume and complexity of patient management. A growing caseload necessitates scalable, efficient systems to minimize errors, standardize care pathways, and manage the intricate logistics of treatment cycles, fueling demand for robust OIS solutions.

The rapid evolution of cancer therapeutics is a powerful catalyst for OIS adoption and sophistication. The shift toward personalized medicine, biomarker-driven therapy, and complex multimodal regimens (combining radiation, immunotherapy, and targeted agents) generates vast, heterogeneous data. Modern OIS platforms are essential for managing this complexity, tracking genomic results, calculating precise drug doses and radiation plans, and ensuring the safe administration of novel agents with unique toxicity profiles.

Technological convergence is a key growth vector. Advancements in interoperability standards (e.g., HL7, FHIR), cloud computing, and data analytics are transforming OIS capabilities. Integration with diagnostic imaging (PACS), laboratory systems, and genomic databases creates a holistic patient view. The incorporation of artificial intelligence and machine learning for tasks like auto-contouring in radiation planning, predictive analytics for patient risk stratification, and clinical decision support is moving OIS from administrative tools to intelligent clinical aids.

The structural shift toward value-based and outcomes-focused cancer care models reinforces the need for sophisticated data capture and analysis. OIS enables the aggregation of real-world evidence, tracking of quality metrics, and reporting required by payers and tumor registries, making it indispensable for demonstrating care quality and cost-effectiveness.

The integration of telemedicine and remote monitoring capabilities, accelerated by recent healthcare delivery trends, has become a critical feature. OIS platforms now support virtual consultations, remote patient-reported outcome (PRO) collection, and telehealth coordination, extending the reach of oncology expertise and facilitating continuous care management outside the clinic.

Market Restraints and Implementation Challenges

The market faces significant barriers related to system integration and resource constraints. Implementing and maintaining an OIS requires substantial capital investment, dedicated IT support, and extensive user training. Integrating the OIS with a hospital's existing enterprise EHR, pharmacy, and billing systems is often a complex, time-consuming, and costly undertaking, potentially leading to workflow disruptions.

Furthermore, disparities in healthcare infrastructure can limit adoption. Resource-constrained or rural facilities may lack the financial means, reliable high-speed internet, or specialized IT personnel required for advanced OIS platforms, creating a digital divide in access to these operational tools.

Geographic Landscape and Adoption Patterns

North America represents a mature and dominant market, characterized by high cancer care expenditure, early adoption of digital health technologies, and a complex regulatory and reimbursement environment that necessitates robust data management. The presence of leading OIS vendors, integrated cancer networks, and significant investment in healthcare IT consolidates the region's leadership.

Other developed regions and select high-growth markets are also advancing adoption, driven by national cancer control plans, investments in centralized cancer centers, and the need to improve care coordination and data collection for research and public health monitoring.

Competitive Landscape and Strategic Evolution

The competitive environment includes specialized oncology software firms and large healthcare IT corporations with dedicated oncology divisions. Differentiation is achieved through depth of clinical functionality-particularly in advanced radiation therapy planning and complex systemic therapy management-seamless interoperability, user experience, and robust analytics and reporting modules.

Strategic initiatives focus on developing cloud-native platforms to reduce IT burden on clinics, expanding AI-powered clinical tools, and creating modular systems that can scale from community practices to large academic centers. Partnerships with pharmaceutical companies and clinical research organizations to streamline trial recruitment and data management are also a growing strategic focus.

Future Market Trajectory

The future trajectory of the OIS market is oriented toward greater intelligence, interoperability, and patient-centricity. OIS will evolve into predictive clinical operating systems, leveraging aggregated data to suggest personalized treatment pathways and identify patients at risk for complications or hospital readmission.

Enhanced patient portals and mobile integration will empower patients as active participants in their care. Furthermore, the role of OIS in enabling decentralized clinical trials and real-world evidence generation will expand significantly. Success for vendors will hinge on demonstrating a clear return on investment through improved operational efficiency, enhanced patient safety, and support for high-quality, coordinated care. As oncology becomes increasingly data-driven and multimodal, the OIS market is poised for sustained growth as the essential digital infrastructure underpinning effective, efficient, and equitable cancer care delivery.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Oncology Information Systems Market Segmentation:

By Product
Solutions
Professional Services
By Application
Medical Oncology
Radiation Oncology
Surgical Oncology
By End-User
Hospitals & Diagnostic Imaging Centers
Government Institutions
Research Facilities
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. ONCOLOGY INFORMATION SYSTEMS MARKET, BY PRODUCT

5.1. Introduction
5.2. Solutions
5.3. Professional Services

6. ONCOLOGY INFORMATION SYSTEMS MARKET, BY APPLICATION

6.1. Introduction
6.2. Medical Oncology
6.3. Radiation Oncology
6.4. Surgical Oncology

7. ONCOLOGY INFORMATION SYSTEMS MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals & Diagnostic Imaging Centers
7.3. Government Institutions
7.4. Research Facilities

8. ONCOLOGY INFORMATION SYSTEMS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others